""While the clinical potential of the gut microbiome is well understood, transforming microbiome-based therapeutics into a scalable product has remained a significant engineering challenge," said Dr. Johannes B. Woehrstein, CEO and co-founder of mbiomics."
""At mbiomics, we are solving this challenge by building the full technology stack for the design, analysis, screening, and manufacturing of complex microbial consortia.""
""Its core product class is Live Biotherapeutic Products (LBPs), oral therapeutics composed of defined combinations of live bacterial strains, delivered in a pharmaceutical-grade format.""
mbiomics GmbH, a Munich-based techbio company, has raised €30 million in Series A funding to develop microbiome-based therapeutics. The latest €12 million tranche will support the pharmacological data package for lead candidate MBX-116 and accelerate GMP-grade manufacturing for clinical trials. A Phase 1B study in advanced melanoma is planned for 2027. The company aims to address engineering challenges in creating scalable microbiome-based therapeutics by building a comprehensive technology stack for microbial consortia design and manufacturing.
Read at TNW | Health-Tech
Unable to calculate read time
Collection
[
|
...
]